New drug combo shows promise for advanced prostate cancer across races
NCT ID NCT03098836
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a combination of two drugs, apalutamide and abiraterone, plus prednisone, in 93 men with advanced prostate cancer that had spread and was no longer responding to hormone therapy. The goal was to see how long the cancer stayed under control and whether the drugs worked similarly in African American and Caucasian men. The men took the drugs daily in 4-week cycles, and the study tracked their cancer progression and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
apalutamide and abiraterone acetate (with prednisone)
What this could lead to
If successful, this could show that a two-drug combination works well for advanced prostate cancer in both Black and White men, potentially leading to more personalized treatment.
What could go wrong
This is a small, early-phase study (Phase 2) with only 93 men, so results may not apply to everyone. The drugs can cause side effects like high blood pressure and fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Chesapeake Urology Associates
Baltimore, Maryland, 21204, United States
-
Duke Cancer Center Cary
Cary, North Carolina, 27518, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Johnston Hematology and Oncology of Clayton
Clayton, North Carolina, 27520, United States
-
Johnston Memorial Hospital
Smithfield, North Carolina, 27577, United States
-
Maria Parham Hospital
Henderson, North Carolina, 27536, United States
-
Scotland Memorial Hospital
Laurinburg, North Carolina, 28352, United States
-
Southeastern Regional
Lumberton, North Carolina, 28358, United States
-
Spartanburg Regional
Spartanburg, South Carolina, 29303, United States
-
Tulane University
New Orleans, Louisiana, 70112, United States
-
UNC Lineberger Cancer Center
Chapel Hill, North Carolina, 27514, United States
-
Virginia Oncology Associates
Hampton, Virginia, 29303, United States
-
Virginia Oncology Associates
Norfolk, Virginia, 23502, United States